Ken Griffin Kal Vista Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,900 shares of KALV stock, worth $19,285. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,900

Previous 9,300 79.57%

Holding current value

$19,285

Previous $109,000 79.82%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$9.46 - $15.39 $1.03 Million - $1.67 Million	108,427 Added 576.07%	127,249 $1.47 Million
Q2 2024 Aug 14, 2024	SELL	$10.35 - $12.49 $706,511 - $852,592	-68,262 Reduced 78.39%	18,822 $221,000
Q1 2024 May 15, 2024	SELL	$11.07 - $16.04 $7.71 Million - $11.2 Million	-696,614 Reduced 88.89%	87,084 $1.03 Million
Q4 2023 Feb 14, 2024	SELL	$7.58 - $12.25 $1.1 Million - $1.77 Million	-144,804 Reduced 15.6%	783,698 $9.6 Million
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $732,969 - $929,519	81,896 Added 9.67%	928,502 $8.94 Million
Q2 2023 Aug 14, 2023	BUY	$7.73 - $10.57 $5.55 Million - $7.59 Million	718,211 Added 559.38%	846,606 $7.62 Million
Q1 2023 May 15, 2023	BUY	$6.3 - $8.39 $169,268 - $225,422	26,868 Added 26.46%	128,395 $1.01 Million
Q4 2022 Feb 14, 2023	SELL	$4.2 - $14.24 $159,579 - $541,048	-37,995 Reduced 27.23%	101,527 $686,000
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $332,526 - $568,163	-33,759 Reduced 19.48%	139,522 $2.02 Million
Q2 2022 Aug 15, 2022	BUY	$8.16 - $15.1 $900,137 - $1.67 Million	110,311 Added 175.18%	173,281 $1.71 Million
Q1 2022 May 16, 2022	BUY	$11.2 - $16.97 $510,316 - $773,221	45,564 Added 261.77%	62,970 $928,000
Q4 2021 Feb 14, 2022	SELL	$12.36 - $18.28 $287,444 - $425,119	-23,256 Reduced 57.19%	17,406 $230,000
Q3 2021 Nov 15, 2021	SELL	$17.11 - $24.49 $602,032 - $861,705	-35,186 Reduced 46.39%	40,662 $710,000
Q2 2021 Aug 16, 2021	BUY	$23.12 - $29.91 $703,703 - $910,370	30,437 Added 67.03%	75,848 $1.82 Million
Q1 2021 May 17, 2021	BUY	$14.69 - $42.57 $667,087 - $1.93 Million	45,411 New	45,411 $1.17 Million
Q2 2020 Aug 14, 2020	SELL	$6.75 - $12.89 $631,145 - $1.21 Million	-93,503 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.8 - $18.56 $542,317 - $1.74 Million	93,503 New	93,503 $715,000
Q4 2019 Feb 14, 2020	SELL	$10.31 - $17.81 $105,100 - $181,555	-10,194 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$11.6 - $21.67 $126,184 - $235,726	-10,878 Reduced 51.62%	10,194 $118,000
Q2 2019 Aug 14, 2019	BUY	$18.44 - $30.89 $388,567 - $650,914	21,072 New	21,072 $467,000

Others Institutions Holding KALV

# of Institutions

125

Shares Held

47.8M

Call Options Held

551K

Put Options Held

110K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $250M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account